FDA Approves BRACAnalysis CDx Companion Diagnostic Assay for Olaparib in Breast Cancer Treatment
March 15th 2022BRACAnalysis CDx assay is indicated for use as a companion diagnostic to select patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer who may derive clinical benefit from olaparib.
Read More
Phase 3 Trial Paused for CP101 in Recurrent C. difficle Infection
March 11th 2022Finch was still able to continue dosing patients in its past-ongoing PRISM-EXT phase 2 open-label trial of CP101 in recurrent CDI, because the CP101 lots used for PRISM-EXT were manufactured from material donated prior to December 1, 2019.
Read More